Ysios capital riesgo

AM-Pharma B. AKI is a devastating disease, with a high mortality rate which affects millions of patients worldwide and has no approved pharmacological treatments. The most important cause of AKI is sepsis. The Cowen team not only provides additional funds but also vast experience that can be drawn upon.

ysios capital riesgo

We are also delighted with the award of funds from the EIB which is a great supporter of innovative medicines and will enable the building of our company. We believe that recAP has the potential to be an important treatment option for AKI and other indications of high unmet medical need.

Invalid escape character in string jsonc 261

We look forward to working with the team and the rest of the investors throughout the Phase III trial and beyond. Acute kidney injury: an increasing global concern. Intensive Care Med ;— All Rights Reserved. Terms of Service Privacy Policy. Subscribe to Directory. Highlight Popular Recent. Photos Stream. About us Capital-Riesgo.

Packetbeat flows

Monthly Newsletter Subscribe to our newsletter and stay up to date with the latest news and deals! Contact us Capital-Riesgo. Deu i Mata, Barcelona, Barcelona P: 93 88 Buy Avodartwhere to buy Nolvadex is actively used for the treatment of the breast cancer, by women during menopause.

Funding will be used to support go-to-market activities in Europe. DiagCORE is a fully integrated molecular and immunoassay diagnostics system that delivers lab-like performance in just one step, providing unrivaled usability for true walk-away diagnostics. DiagCORE performs all sample prep steps on board for a wide range of sample types e. Time to results can be as low as 30 and up to 80 minutes, depending on the assay type. The system will also have CLIA-waivable features that will allow it to be used in clinics and physician offices.

Its DiagCORE in vitro diagnostic system is a versatile, easy-to-use platform that consolidates molecular and immunoassay techniques in a single device. Download pdf English. Ysios Capital.


This website uses cookies to track its audience and improve its content. By continuing to browse this website, you agree to the use of such cookies. For more information on cookies check the legal notice I agree.The phase II trials w ill start in and will take place in specialist centers in Europe and the US.

PD is a devastating progressive neurological condition affecting around 6. The disease is caused by the degeneration of dopaminergic brain cells.


The main symptoms are resting tremor, muscle rigidity ' OFF - time ' and uncontrolled movements ' Dyskinesia '. Current treatments aim to replace dopamine or to mimic its effects.

Th is treatment provides adequate symptomatic relief initially, but over time, it loses efficacy as the disease progresses and patients experience serious debilitating side effects, such as dyskinesia.

Instead of targeting the dopaminergic systemFoliglurax activates a specific target of the glutamatergic system mGluR4. The aim is to treat the motor symptoms of PD. A phase I trial with Foliglurax was successfull y completed in September The results showed that Foliglurax was safe and well - tolerated at doses well above those that produce robust effects in PD primate models. We look forward to working with the team.

This creates very challenging issues for patients. We were attracted to Prexton by its potential to help address this significant unmet clinical and commercial need. Parkinson's disease is a chronic and progressive neurological disorder affecting around 6. Parkinson's disease is more p revalent in people over 60 and the incidence of the disease is expected to increase as the average age of the population increases. It is estimated that more than one million people in the United States 2 live with the disease and three millions in the Euro pean Union.

It is dominated by matured Dopaminergic treatments, which frequently induce negative side effects. There is an overall consensus in the field supporting the development of more efficient approaches, while limiting or even abolishing the occurr ence of adverse effects.

Prexton Therapeutics is a biopharmaceutical company, founded in by Francois Conquet and Merck Ventures. It is part of a Merck Ventures entrepreneurial partnership programwhich support s the creation of spin - offs from Merck. Forbion Capital Partners is a dedicated life sciences venture capital firm with offices in The Netherlands and Germany.

Forbion invests in life sciences companies in the pharmaceutical as well as the medical device space. Forbion also operates a joint venture with BioGeneration Ventures, who manag e two separate seed and early stage funds focused on Benelux. Seroba is a European life sciences venture capital firm. It is focused on investing in breakthrough healthcare technologies that promise to improve lives and clinical outcomes.

Carlini m, lepiane p, calisti a, santoro r, carboni f, and

Seroba fund s new healthcare opportunities thr ough key value - adding stages from inception through development, clinical evaluation and early commercialisation. It help s its investee companies to grow and support s them through their development journey, helping them to prepare for market launch or for partnering with leading medtech or pharma companies.

AM-Pharma Increases Funding to €163m for Phase-III Trial of recAP in SA-AKI

Sunstone Capital is a leading pan - European venture capital investor founded in by an internat ional team of industry experts with combined entrepreneurial, operational and financial experience. Sunstone Capital focuses on developing and expanding early - stage life science and technology companies with strong potential to achieve global success.

With in life science, Sunstone Capital has invested in more than 50 companies in the areas of pharmaceuticals, medical technologies and diagnostics.

Ysios Capital is a leading Spanish venture capital firm that provides private equity financing to early - and mid-stage human healthcare and life science companies with a special focus on pharmaceuticals, diagnostics and medical devices.Ysios Capital is a leading Spanish independent venture capital firm that provides private equity financing to early- and mid-stage human healthcare and life science companies.

We target the entire healthcare and biotechnology industry, with a special focus on pharmaceuticals, diagnostics and medical devices. Our team includes experienced professionals with extensive complementary expertise in investing and building healthcare and biotechnology companies. Ysios Capital has access to a broad global network within academia, finance and industry.

We take an active role in the development of our portfolio companies as a lead investor or as an active syndicate partner. Its main office is in Barcelona.

Apadrinant el talent - Ysios Capital i Edwin David Hurtado

Ysios Capital has an experienced and dedicated hands-on team with a proven track record. From evaluating clinical programs or early technologies to providing expert advice on licensing agreements, Ysios brings a wealth of industry-specific expertise and knowledge in finance, venture capital and science.

Our investments target companies that focus on product development in the biotechnology, emerging pharmaceuticals, healthcare and medical technology sectors. Ysios Capital has a clearly defined investment strategy: we focus on investing in human healthcare innovation projects in and outside of Spain. We aim to balance risk and liquidity against the stage of investment, from seed capital to pre-IPO-investing, in various subsectors with different time-to-market horizons, capital needs and risk-to-return ratios.

For investments in Spain, we typically act as the lead investor, structuring the transaction and always syndicating with other venture capital firms. In major financing operations, especially in those circumstances where we can leverage our global network, we seek to invest in international syndicates with other dedicated life sciences and healthcare investors that share our vision and commitment to investing in and supporting companies. Management team While we acknowledge that a management team is seldom complete, we like to invest in a cohesive management team with a proven track record, including relevant business experience and top-notch scientific know-how.

Products We invest almost exclusively in product development projects; we rarely invest in services. Products in clinical or preclinical development should have an attractive market potential or, if a niche indication is targeted, its potential market share should be significant and realistic. Ideally, we like to invest in companies that have a platform technology capable of generating new product candidates on a sustainable basis with a competitive advantage.

Milestones The business plan should clearly outline the principal milestones to be achieved in 2 to 3 years e. Such milestones should be realistic. Strong entry barriers Intellectual property is an important asset of biotech and pharmaceutical companies. Ideally, the company should have freedom to operate.

Coronavirus, oltre 200mila morti in tutto il mondo, 2,8 mln casi

Syndication We seek lead investor roles in first rounds of financing in Spain. In large rounds of financing, we usually take a follower role in syndicates with top-tier biotech venture capital firms, although we occasionally lead deals outside of Spain. Our team is dedicated to an open and reliable collaborative investment approach following a standardised process for all investment decisions. Based on the results of this analysis, we perform comprehensive due diligence and assessment. If we decide to proceed, we will present a term sheet establishing the terms of investment.

ysios capital riesgo

Confidentiality At Ysios Capital, confidentiality is important to us, just as it is to the companies that approach us. We strive to ensure that any information provided to us remains strictly confidential.Sanifita clinical-stage biopharmaceutical company focused on treatments for progressive vascular calcification disorders, today announced that the international Phase 2b CaLIPSO study of SNF in patients with end stage kidney disease ESKD on hemodialysis has met its primary endpoint.

The study demonstrated a reduction in coronary artery calcium CAC volume in patients treated with SNF as compared to patients receiving placebo over a week period. We look forward to presenting the topline data at AHA and continuing our efforts in the development of SNF as a novel treatment for disorders related to cardiovascular calcification in ESKD patients on hemodialysis.

Glenn M. Slides will be available on the Sanifit website shortly before the webcast. SNF is an intravenous formulation of myo-inositol hexaphosphate with a novel mechanism of action for the treatment of haemodialysis patients with cardiovascular diseases linked to calcification. SNF is being developed for two indications: calciphylaxis and cardiovascular disease in end stage renal disease CV-ESRD patients undergoing dialysis.

SNF selectively blocks the progression of pathological cardiovascular calcification, and poses an innovative solution for these unmet medical needs. Sanifit is a biopharmaceutical company focused on calcification disorders. The company launched in as a spin-off from the University of the Balearic Islands and expanded its activities in the USA in with the incorporation of a subsidiary with offices in San Diego. Save my name, email, and website in this browser for the next time I comment.

Publicar comentario. Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Saltar al contenido. About Sanifit Sanifit is a biopharmaceutical company focused on calcification disorders.A really fabulous start to my Scandinavian adventure and the nutshell tour set the scene. We really enjoyed our stay in all of the accommodations. Everything was very clean and comfortable. All of the tours we participated in were well run. The staff were very friendly and professional.

His email replies were always timely and informative. Thanks for making our trip to Iceland so unforgettable. We both hope to return. The service we received at all our locations was excellent and the free upgrades were much appreciated and very unexpected.

We absolutely loved the tour of Iceland. It was awesome to have everything booked and set up for us in advance, but doing the self-drive tour gave us a lot of flexibility about what we wanted to do from day to day. It also let us really see the country and experience parts of it that probably aren't normally seen by tourists.

ysios capital riesgo

Booking through Nordic Visitor made everything easy and let us just truly enjoy the experience. It has been a truly memorable visit and journey and I had always wanted to see Iceland. The trip was even more fantastic than I had imagined. I now have plenty of memories, photos and drawings to feed my work as an artist. Great trip, enjoyed the freedom of not having to worry about tour guides and groups while on the holiday, but having the luxury of someone with local knowledge make all the bookings and design the itinerary.

The annotated map was great, the phone a life-saver. You have fantastic customer service.

Lydiard gloss white large shoe cabinet

Anita was very helpful leading up to our trip.There is always going to be overlap. The ship may be a different tier, or have some other characteristics that make it different.

Didn't she was the same as the Richelieu. I think the US refit of Richelieu would be better as a premium but as it's head of class and Dunkerque, already in the game (also head of class) it won't happen. They won't put two of the last french BBs as premiums if they want to make a french BB line (they have the material). In term of unique flavor, Jean Bart would be the very same as stock Richelieu, that's why I don't understand it as a Premium choice.

Richelieu all the way. That US AA refit. It will be god tier. Gascogne would've had two turrets like Richelieu and Jean Bart but with one facing forward and one facing aft. The armor is rather weak already, why make it worse by showing more broadside to have the aft turret shoot. It's Graf Spee all over again. Why loose the flavor and strenght of the full frontal turrets. I don't know if the Jean Bart offers something sufficiently different or special to sell it while having the ship's class in the tech tree.

But there's the Prinz Eugen, so t could happen. Weaknesses would be it's lacking long range AA, low number of secondaries, and, despite supercharges, still sporting just 8 15 inch guns at T8.

Guessing that she will also get a radar consumable due to being the last Battleship ever built (Jean Bart really doesn't count). For this reason, sources which quote HMS Vanguard as having gun ranges in excess of 32,000 yards (29,260 m) are somewhat misleading, as such a range would have required the use of super charges, which she never carried.

She was a Franken-ship made from spare hull and guns, although she was built I think her strange construction could easily lend to creative balancing.

Honestly I think there would be a lot of hate for releasing Vanguard at tier 8 price tag and she didn't feel good to play. We dont need a tier 8 Krazny Krym. Maryland got more AA. West Virginia got more AA, enhanced radar, thicker decks, better torpedo defenses, and so forth. In effect, she was a new ship built atop the old. With the right tweaks, such as more accurate guns and possibly radar, she would make a decent tier 8 premium.


Leave a Reply

Your email address will not be published. Required fields are marked *